Eli Lilly's oral weight loss drug phase III data released: average weight loss of 10.5%, will initiate global filing
I'm PortAI, I can summarize articles.
Eli Lilly announced that its oral weight loss drug orforglipron achieved its primary goal in Phase III clinical trials, with an average weight loss of 10.5% over 72 weeks. The drug will initiate global registration filings, with trials covering over 1,600 obese or overweight patients with type 2 diabetes, achieving all primary and secondary endpoints. The safety profile of orforglipron is consistent with other GLP-1 receptor agonists, but the treatment discontinuation rate is slightly higher. Complete study results will be presented at future medical conferences
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments